These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

744 related items for PubMed ID: 28902041

  • 1. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M.
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
    [Abstract] [Full Text] [Related]

  • 2. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
    Guerra Veloz MF, Vázquez Morón JM, Belvis Jiménez M, Pallarés Manrique H, Valdés Delgado T, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino V, Caunedo Álvarez Á, Argüelles Arias F.
    Rev Esp Enferm Dig; 2018 Sep; 110(9):564-570. PubMed ID: 29893581
    [Abstract] [Full Text] [Related]

  • 3. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F.
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [Abstract] [Full Text] [Related]

  • 4. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Nov; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

  • 5. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR, SECURE study group.
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [Abstract] [Full Text] [Related]

  • 6. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A, Huoponen S, Pahikkala T, Blom M, Arkkila P, Sipponen T.
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [Abstract] [Full Text] [Related]

  • 7. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ.
    Expert Rev Gastroenterol Hepatol; 2015 Dec; 9 Suppl 1():35-44. PubMed ID: 26395533
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
    Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML.
    J Crohns Colitis; 2017 Mar 01; 11(3):297-304. PubMed ID: 27660339
    [Abstract] [Full Text] [Related]

  • 10. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, Milassin Á, Fábián A, Szántó K, Végh Z, Kürti Z, Lakatos PL, Szepes Z, Molnár T.
    Expert Opin Biol Ther; 2017 Nov 01; 17(11):1325-1332. PubMed ID: 28819991
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.
    Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.
    Dig Dis Sci; 2017 Nov 01; 62(11):3117-3122. PubMed ID: 28667429
    [Abstract] [Full Text] [Related]

  • 12. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW.
    Scand J Gastroenterol; 2018 Jun 01; 53(6):692-699. PubMed ID: 29852793
    [Abstract] [Full Text] [Related]

  • 13. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J.
    Scand J Gastroenterol; 2016 Sep 01; 51(9):1062-8. PubMed ID: 27002981
    [Abstract] [Full Text] [Related]

  • 14. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL.
    Eur J Gastroenterol Hepatol; 2018 Jul 01; 30(7):699-703. PubMed ID: 29538037
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
    Bronswijk M, Moens A, Lenfant M, Tops S, Compernolle G, Van Assche G, Vermeire S, Gils A, Ferrante M.
    Inflamm Bowel Dis; 2020 Mar 04; 26(4):628-634. PubMed ID: 31400283
    [Abstract] [Full Text] [Related]

  • 18. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M, Duricova D, Bortlik M, Hruba V, Machkova N, Mitrova K, Malickova K, Lukas M, Lukas M.
    Dig Dis; 2017 Mar 04; 35(1-2):91-100. PubMed ID: 28147356
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.